
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 5.890 | 5.900 | 0.010 |
Shares | 94.070 | 94.070 | 0.000 |
Other | 0.040 | 0.040 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.130 | 18.151 |
Price to Book | 4.341 | 3.016 |
Price to Sales | 3.191 | 2.265 |
Price to Cash Flow | 16.534 | 12.091 |
Dividend Yield | 1.988 | 2.388 |
5 Years Earnings Growth | 8.035 | 10.165 |
Name | Net % | Category Average |
---|---|---|
Industrials | 26.340 | 21.689 |
Financial Services | 24.110 | 20.127 |
Technology | 16.920 | 14.711 |
Healthcare | 9.890 | 10.358 |
Basic Materials | 7.000 | 6.278 |
Communication Services | 6.000 | 5.889 |
Consumer Cyclical | 5.610 | 9.947 |
Consumer Defensive | 4.140 | 7.358 |
Number of long holdings: 55
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Relx | GB00B2B0DG97 | 3.38 | 3,446.00 | -1.40% | |
Schneider Electric | FR0000121972 | 3.23 | 210.05 | -1.71% | |
EssilorLuxottica | FR0000121667 | 3.11 | 260.20 | -1.21% | |
Deutsche Boerse | DE0005810055 | 2.88 | 251.600 | -0.83% | |
SAP | DE0007164600 | 2.87 | 231.700 | -1.97% | |
Diploma | GB0001826634 | 2.79 | 5,400.00 | -0.55% | |
Wolters Kluwer | NL0000395903 | 2.68 | 107.60 | -1.56% | |
Safran | FR0000073272 | 2.56 | 284.90 | -1.01% | |
AstraZeneca | GB0009895292 | 2.53 | 11,790.0 | -0.17% | |
Partners Group | CH0024608827 | 2.43 | 1,097.50 | -1.57% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Norrep Global Income Growth Class A | 244.69M | 3.92 | 11.37 | 7.18 | ||
Norrep Global Income Growth Class F | 244.69M | 4.57 | 12.57 | 8.31 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review